Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Witkowski

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Biomedicines|January 21, 2023
Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial FibrillationLeon Blöbaum, Marco Witkowski, Max Wegner, et al.
International Journal of Molecular Sciences|April 13, 2024
Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial FibrillationJulian Friebel, Max Wegner, Leon Blöbaum, et al.
Cells|January 8, 2023
Cytotoxic CD8<sup>+</sup> T Cells Are Involved in the Thrombo-Inflammatory Response during First-Diagnosed Atrial FibrillationJulian Friebel, Marco Witkowski, Max Wegner, et al.
Cardiovascular Diabetology|February 19, 2020
Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetesMarco Witkowski, Mario Witkowski, Mona Saffarzadeh, et al.
European Journal of Heart Failure|December 21, 2023
Prognostic value of gut microbe-generated metabolite phenylacetylglutamine in patients with heart failureW H Wilson Tang, Ina Nemet, Xinmin S Li, et al.
European Heart Journal|June 21, 2023
Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortalityIna Nemet, Xinmin S Li, Arash Haghikia, et al.
Cells|December 24, 2021
Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular InflammationJulian Friebel, Eileen Moritz, Marco Witkowski, et al.
Nature Medicine|February 28, 2023
The artificial sweetener erythritol and cardiovascular event riskMarco Witkowski, Ina Nemet, Hassan Alamri, et al.
European Heart Journal|April 21, 2019
Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunctionJulian Friebel, Alice Weithauser, Marco Witkowski, et al.
Nature Medicine|March 6, 2024
Publisher Correction: A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease riskMarc Ferrell, Zeneng Wang, James T Anderson, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Biomedicines|January 21, 2023
Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial FibrillationLeon Blöbaum, Marco Witkowski, Max Wegner, et al.
International Journal of Molecular Sciences|April 13, 2024
Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial FibrillationJulian Friebel, Max Wegner, Leon Blöbaum, et al.
Cells|January 8, 2023
Cytotoxic CD8<sup>+</sup> T Cells Are Involved in the Thrombo-Inflammatory Response during First-Diagnosed Atrial FibrillationJulian Friebel, Marco Witkowski, Max Wegner, et al.
Cardiovascular Diabetology|February 19, 2020
Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetesMarco Witkowski, Mario Witkowski, Mona Saffarzadeh, et al.
European Journal of Heart Failure|December 21, 2023
Prognostic value of gut microbe-generated metabolite phenylacetylglutamine in patients with heart failureW H Wilson Tang, Ina Nemet, Xinmin S Li, et al.
European Heart Journal|June 21, 2023
Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortalityIna Nemet, Xinmin S Li, Arash Haghikia, et al.
Cells|December 24, 2021
Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular InflammationJulian Friebel, Eileen Moritz, Marco Witkowski, et al.
Nature Medicine|February 28, 2023
The artificial sweetener erythritol and cardiovascular event riskMarco Witkowski, Ina Nemet, Hassan Alamri, et al.
European Heart Journal|April 21, 2019
Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunctionJulian Friebel, Alice Weithauser, Marco Witkowski, et al.
Nature Medicine|March 6, 2024
Publisher Correction: A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease riskMarc Ferrell, Zeneng Wang, James T Anderson, et al.
Pageof 4